Compare Danaher Corporation (DHR) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs State Street SPDR S&P Homebuilders ETF — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while State Street SPDR S&P Homebuilders ETF trades at $108.31. The key difference: Danaher Corporation pays a 0.77% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals.
| DHR | XHB | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $242.05 | $121.36 |
52-Week Low | $161.91 | $94.86 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
XHB trades at $108.71 with a modest 0.43% daily gain, showing bullish technical momentum with strong moving average signals. The ETF benefits from positive housing market developments including new home sales growth and supportive legislation, though mixed economic data creates uncertainty. Technical indicators show overbought conditions with RSI at 71.56, suggesting potential near-term consolidation.
The housing sector outlook remains cautiously optimistic with legislative support and improving builder sentiment offsetting high mortgage rate concerns. Key risks include interest rate sensitivity and inventory constraints, while institutional positioning adjustments reflect strategic portfolio rebalancing rather than sector pessimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
